Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: James Perry who wrote (1326)	10/22/1997 10:38:00 PM
From: Richard Cohen	Read Replies (1) \| Respond to of 1762

Jim- You could buy now or wait for the split. I think the biotech mutual funds are salivating waiting to get in. Right now they can't touch the stock because of the low float. Remember this is pending FDA approval for Hextend but it flerw through FDA trials without a hitch. I'm a physician and I really can appreciate the potential of this product. Go to Motley Fool boards for complete history of the product but it looks like a sure thing (if that exists?) Abbott thiks so because they already paid a wad of cash and apparently are building production sites for Hextend. BTIM just has to sit back and cash the 35% royalty checks. Good luck on your decision. BTW, what other Biotechs look good to you now. I always like to do a little investigation for fun (or maybe profit?) Rich